File downloaded on 2026-06-14
Source URL: https://medicines.health.europa.eu/veterinary/en/600000032723

Pergoquin, 1 mg tablets for horses

Authorised

- Pergolide mesilate

Product identification

Medicine name:
Pergoquin, 1 mg tablets for horses

Active substance:
Pergolide mesilate

Target species:
Horse

Route of administration:
Oral use

Product details

Active substance and strength:
Pergolide mesilate
1.31 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN04BC02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Hungary

Available in:
Hungary

Package description:
Cardboard box of 200 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.
Cardboard box of 160 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.
Cardboard box of 150 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.
Cardboard box of 100 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.
Cardboard box of 50 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.
Cardboard box of 60 tablets containing Aluminium-OPA, Aluminium, PVC blisters containing 10 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Vetviva Richter GmbH

Marketing authorisation date:
10/09/2019

Manufacturing sites for batch release:
Lelypharma B.V.

Responsible authority:
Directorate Of Veterinary Medicinal Products

Authorisation number:
4097/x/19 NÉBIH ÁTI

Date of authorisation status change:
10/09/2019

Reference member state:
Netherlands

Procedure number:
NL/V/0295/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents